Literature DB >> 8057129

Apomorphine induced cognitive changes in Parkinson's disease.

E Růzicka1, J Roth, N Spacková, P Mecír, R Jech.   

Abstract

Auditory event related potentials (ERPs) and visual evoked potentials (VEPs) were recorded from eight patients with Parkinson's disease, before and after a single dose of apomorphine. To assess the treatment effects, the patients' motor state, Benton visual retention test (BVRT), and digit span tests were also examined. After apomorphine, although motor performance improved, the ERP latencies were delayed and the N2-P3 ERP amplitude was significantly diminished by comparison with pretreatment values. These data suggest that apomorphine induces, besides its motor effects in patients with Parkinson's disease, a slowing down of cognitive processing. Preferential stimulation of dopamine autoreceptors in mesocortical and mesolimbic systems may represent a neural mechanism for these effects. Also, the posttreatment BVRT rotation errors significantly increased, suggesting an apomorphine induced impairment of visuospatial perception.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057129      PMCID: PMC1073092          DOI: 10.1136/jnnp.57.8.998

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  [Correlation of visual evoked potentials with dementia in Parkinson's disease].

Authors:  B Okuda; H Tachibana; K Kawabata; M Takeda; K Toda; M Sugita
Journal:  Nihon Ronen Igakkai Zasshi       Date:  1992-06

2.  Augmenting mental chronometry: the P300 as a measure of stimulus evaluation time.

Authors:  M Kutas; G McCarthy; E Donchin
Journal:  Science       Date:  1977-08-19       Impact factor: 47.728

3.  Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease.

Authors:  S E Starkstein; M Esteguy; M L Berthier; H Garcia; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

4.  A triarchic model of P300 amplitude.

Authors:  R Johnson
Journal:  Psychophysiology       Date:  1986-07       Impact factor: 4.016

Review 5.  Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients.

Authors:  I Bodis-Wollner
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

6.  Cognition in Parkinson disease: an event-related potential perspective.

Authors:  E C Hansch; K Syndulko; S N Cohen; Z I Goldberg; A R Potvin; W W Tourtellotte
Journal:  Ann Neurol       Date:  1982-06       Impact factor: 10.422

7.  High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.

Authors:  W Poewe; W Berger; T Benke; L Schelosky
Journal:  Ann Neurol       Date:  1991-06       Impact factor: 10.422

8.  Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.

Authors:  D Prasher; L Findley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-07       Impact factor: 10.154

9.  Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.

Authors:  U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

10.  Electrophysiological differences between demented and nondemented patients with Parkinson's disease.

Authors:  D S Goodin; M J Aminoff
Journal:  Ann Neurol       Date:  1987-01       Impact factor: 10.422

View more
  5 in total

1.  Dopaminergic stimulation in unilateral neglect.

Authors:  G Geminiani; G Bottini; R Sterzi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

2.  Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys.

Authors:  B L Murphy; A F Arnsten; P S Goldman-Rakic; R H Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

Review 3.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

4.  Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease.

Authors:  Luca Passamonti; Maria Salsone; Nicola Toschi; Antonio Cerasa; Marco Giannelli; Carmelina Chiriaco; Giuseppe Lucio Cascini; Francesco Fera; Aldo Quattrone
Journal:  Brain Behav       Date:  2013-03-22       Impact factor: 2.708

5.  The detection of novelty relies on dopaminergic signaling: evidence from apomorphine's impact on the novelty N2.

Authors:  Mauricio Rangel-Gomez; Clayton Hickey; Therese van Amelsvoort; Pierre Bet; Martijn Meeter
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.